Form 4: Tempest Therapeutics Director Receives Stock Option Grant

Director John D. Yee was granted 25,000 stock options in Tempest Therapeutics, Inc. as part of a standard equity compensation package.

Summary

• Director John D. Yee acquired 25,000 stock options in Tempest Therapeutics, Inc. (TPST).
• The options have an exercise price of $1.27 per share.
• The grant date for these options is June 4, 2026.
• The options are set to expire on June 4, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation, despite the minor reporting delay.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The filing was submitted late due to an administrative oversight.

Risks

• Potential dilution of existing shares upon the exercise of these options.
• Market volatility affecting the value of the underlying common stock.

Future Outlook

The options vest over a three-year period, with one-third vesting on the first anniversary of the grant date and the remainder vesting in equal monthly installments thereafter, contingent upon continued service.

Management Comments

• The filing notes that the transaction was reported late due to an inadvertent administrative oversight.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to incentivize long-term strategic oversight and retention of board members.

Comparison to Industry Standards

• The three-year vesting schedule is consistent with standard corporate governance practices for small-cap biotechnology firms.
• The grant size is typical for non-executive director compensation packages in the life sciences industry.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity incentive grant.

Next Steps

• Vesting of the first tranche of options on June 4, 2027.

Key Dates

Keywords

Tempest Therapeutics, TPST, Form 4, Insider Trading, Stock Options, Director Compensation